Biểu đồ giá cổ phiếu ENGN
ENGN Thu nhập
enGene Therapeutics Inc
$1.72
-80.56%
$-7.13
Khi đóng cửa: May 07, 16:00:00 GMT-4
$1.73
0.58%
$0.01
Phiên sau giờ: May 07, 20:00:00 GMT-4
Quay lại
enGene Therapeutics Inc (ENGN) Thu nhập
Thống kê chính
Giá đóng cửa trước
$8.85
Giá mở cửa
$2.14
Phạm vi ngày
$1.7 - $2.24
Phạm vi 52 tuần
$1.73 - $12.25
Khối lượng
23.4M
Khối lượng trung bình
401.2K
Tỷ suất cổ tức
--
EPS (TTM)
-2.25
Vốn hóa thị trường
$115.8M
ENGN là gì?
enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. The company is headquartered in Saint-Laurent, Quebec and currently employs 45 full-time employees. The company went IPO on 2021-12-10. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
